Portland, OR, March 03, 2020 (GLOBE NEWSWIRE) -- The top 10 cancer drugs industry generated $63.61 billion in 2018, and is estimated to reach $129.94 billion by 2026, witnessing a CAGR of 9.8% from 2019 to 2026.
Drivers, restraints, and opportunities
Surge in incidence of cancer across the globe, increase in aging population, and rise in expenditure of government on healthcare infrastructure drive the global top 10 cancer drugs market. However, adverse effects related to usage of cancer usage hinder the market growth. Contrarily, surge in number of pipeline drugs and untapped potential in emerging geographies create new opportunities in the market.
Request Sample Report at https://www.alliedmarketresearch.com/request-sample/6225
Revlimid accounted for highest share in 2018, Keytruda to surpass by 2026
Based on brand, Revlimid contributed to nearly one-sixth of the total share of the global top 10 cancer drugs market in 2018. Opdivo accounted for more than one-tenth of the total market share in terms of revenue in the same year. However, Keytruda is projected to supersede in terms of market share by 2026. Moreover, this type is expected to grow at the fastest CAGR of 23.8% from 2019 to 2026. Opdivo is projected to register the second-highest CAGR of 15.9% during the forecast period.
Russia and Indonesia to maintain its dominance in terms of revenue during the forecast period
In the European region, the global top 10 cancer drugs market across Russia accounted for the highest revenue with nearly $822.7 million in 2018, and will maintain its highest share by 2026. In Asia-Pacific, the market across Indonesia accounted for the highest market share with revenue of nearly $995.25 million in 2018, is expected to maintain its dominance in terms of revenue during the forecast period. However, the market across Nepal is expected to maintain the largest CAGR of 11.4% from 2019 to 2026.
For Purchase Enquiry at https://www.alliedmarketresearch.com/purchase-enquiry/6225
Leading market players
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson (Janssen Global Services, LLC)
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter
Get more information: https://www.alliedmarketresearch.com/library-access
Similar Reports:
Cancer Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Oncology/Cancer Drugs Market: Global Opportunity Analysis and Industry Forecast, 2019- 2026
Cancer Vaccines Market- Global Opportunity Analysis and Industry Forecast, 2019-2026
Gynecological Cancer Drugs Market- Global Opportunity Analysis and Industry Forecast, 2019-2026
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.